MSD Congratulates Senegal on the Successful Launch of its National Immunisation Programme for Human-Papillomavirus (HPV)
MSD (www.MSD.co.za), known as Merck & Co., Inc., (NYSE: MRK) in the United States and Canada, congratulates Senegal on the successful launch of the National Immunisation Programme (NIP) for the Human-Papillomavirus (HPV - the main cause of cervical cancer).[1]
Approximately 530 000 women are diagnosed with cervical cancer around the world each year.[2] In Sub-Saharan Africa (SSA), cervical cancer incidence rates are the highest in the world (the prevalence of HPV in women with normal cytology is at an average of 24% in SSA) and the disease is the most common cause of cancer death among women in the region. [3],[4] HPV16 and 18 are the most common genotypes in cervical cancer in SSA.[5] Although HPV16 and 18 are associated with approximately 70% of cervical cancer cases [6], the various HPV genotypes also contribute to penile cancers, anal cancers, vulvar and vaginal cancers as well as genital warts in men and women respectively.
This is a historic moment for the government and people of Senegal.
Senegal ranks 15th in the world in incidence of cervical cancer. Cervical cancer is the number one cause of cancer mortality among women in Senegal.[7] The launch of the NIP in Senegal is an important step towards achieving the vision of a world where the number of women and men affected by certain HPV-related cancers is greatly reduced. MSD is committed to working with the government of Senegal and other partners on the continent to ensure that this goal becomes a reality.
[1] https://www.CDC.gov/cancer/cervical/pdf/cervical_facts.pdf
[4] https://Academic.oup.com/jid/article/202/12/1789/2192082
[5] https://Academic.oup.com/jid/article/202/12/1789/2192082
[6] http://www.WHO.int/news-room/fact-sheets/detail/human-papillomavirus-(hpv)-and-cervical-cancer
[7] Dykens JA, et al., Implementing visual cervical cancer screening in Senegal. Int. Journal of Womens Health. 2017; 9: 59-67.
Accessed: https://www.NCBI.nlm.nih.gov/pmc/articles/PMC5291333/
Media Contact:
Neren Rau
+27 11 655 3000
neren.rau@merck.com
About MSD:
For more than a century, MSD (www.MSD.co.za), a leading global biopharmaceutical company, has been inventing for life, bringing forward medicines and vaccines for the world’s most challenging diseases. MSD is a trade name of Merck & Co., Inc., with headquarters in Kenilworth, N.J., U.S.A. Through our prescription medicines, vaccines, biologic therapies and animal health products, we work with customers and operate in more than 140 countries to deliver innovative health solutions. We also demonstrate our commitment to increasing access to health care through far-reaching policies, programs and partnerships. Today, MSD continues to be at the forefront of research to advance the prevention and treatment of diseases that threaten people and communities around the world - including cancer, cardio-metabolic diseases, emerging animal diseases, Alzheimer’s disease and infectious diseases including HIV and Ebola.
For more information, visit www.MSD.co.za and connect with us on Twitter (https://twitter.com/MSD_SouthAfrica).
EIN Presswire does not exercise editorial control over third-party content provided, uploaded, published, or distributed by users of EIN Presswire. We are a distributor, not a publisher, of 3rd party content. Such content may contain the views, opinions, statements, offers, and other material of the respective users, suppliers, participants, or authors.
